Compare Micron Technology, Inc. (MU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs TG Therapeutics Inc — how do they compare? Micron Technology, Inc. trades at $1,029.31 (market cap $1.17T), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Micron Technology, Inc. is far larger — about 143.4× TG Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and TG Therapeutics Inc for 16 Days on average.
| MU | TGTX | |
|---|---|---|
Market Cap | $1.17T | $8.16B |
Volume | 29,425,906 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $1.21K | $59.06 |
52-Week Low | $181.60 | $26.94 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | $1.13T | $8.37B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,029, down 5.42% over the past session, despite strong fundamental performance. The stock shows bullish technical signals with robust earnings beats in recent quarters (Q2 2026 EPS of $33.42 vs. $31.77 expected) and exceptional profitability metrics, including a 63.8% net income margin. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus strongly bullish (82.85% buy ratings) and a $1,590 price target, though risks include cyclical memory pricing and potential AI demand normalization. The company's strong cash flow generation ($17.53B operating cash flow in 2025) and expanding margins support continued upside potential for long-term investors.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
